RESUMO
Erlotinib is an epidermal growth factor receptor tyrosine kinase (EGFR-TK) antagonist used in the therapy of non-small cell lung cancer. This agent has been associated with several dermatologic side effects, the most common being acneiform rash involving the face, neck, chest, and back. The occurrence of skin side effects has been correlated with both therapeutic efficacy and increased overall survival in these patients. We report herein unusual erlotinib-induced skin lesions affecting fingers, with a transverse fissure-like appearance and beefy-red laceration-like center. A unique feature is their location on adductor surfaces and more proximal aspects of the phalanges. This erlotinib side effect has not been previously reported in the medical literature.
Assuntos
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Toxidermias , Receptores ErbB/antagonistas & inibidores , Cloridrato de Erlotinib/efeitos adversos , Neoplasias Pulmonares/tratamento farmacológico , Paroniquia , Creme para a Pele/administração & dosagem , Administração Tópica , Carcinoma Pulmonar de Células não Pequenas/patologia , Toxidermias/diagnóstico , Toxidermias/etiologia , Toxidermias/fisiopatologia , Cloridrato de Erlotinib/administração & dosagem , Feminino , Dedos/patologia , Humanos , Neoplasias Pulmonares/patologia , Pessoa de Meia-Idade , Paroniquia/induzido quimicamente , Paroniquia/diagnóstico , Inibidores de Proteínas Quinases/administração & dosagem , Inibidores de Proteínas Quinases/efeitos adversos , Resultado do TratamentoRESUMO
Insulin-like growth factor II (IGF-II) is a major growth factor in brain and is involved in neuroprotection in later life. However, synthesis and delivery of IGF-II to brain by the choroid plexus (CP) in later life is not well understood. This study investigated these issues in old sheep (7-10 years) in comparison to young adult sheep (1-2 years). IGF-II messenger RNA expression at the CP did not change with age although cerebrospinal fluid (CSF) levels fell. 125I-IGF-II uptake in the CP was saturated from either side of the CP, whereas age-related decrease of the uptake was seen at the CSF side but not at the blood side of the CP. The insulin-like growth factor binding protein-2 (IGFBP-2) at 0.01 or 0.1 microg/mL tended to enhance IGF-II uptake at the young CP but not the old CP or other brain tissues, whereas bovine serum albumin generally inhibited the uptake. These age-related changes suggest that the normal autocrine/paracine role of IGF-II at the CP is attenuated with age.
